<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915083</url>
  </required_header>
  <id_info>
    <org_study_id>AMR PH US 2008 PK002</org_study_id>
    <nct_id>NCT00915083</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.</brief_title>
  <official_title>A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether amrubicin is safe and effective in the
      treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics
      of the amrubicin and if it has an effect on the heart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the pharmacokinetics of amrubicin and amrubicinol (metabolite) in plasma, whole blood, and urine in patients given amrubicin as 5 minute IV infusions at 40 mg/m2 for 3 consecutive days; data will be obtained from blood &amp; urine samples</measure>
    <time_frame>Cycle 1: all primary outcome measures are collected during the first 21 days.</time_frame>
    <description>The duration of making measurements during the first cycle is 21 days. All data relating to the primary outcome measure is collected during this time.
There is an optional Extension Phase during which subjects can continue to receive additional 21-day cycles of amrubicin unless there is evidence of tumor progression or unacceptable toxicity. The duration of measurements depends on how long the subject continues on treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the potential effects on the QT/QTc interval in cancer patients when treated with 5 minute IV infusions of amrubicin 40 mg/m2 daily for 3 consecutive days; data will be obtained by ECG extraction from continuous 12-lead Holter monitoring</measure>
    <time_frame>Cycle 1: all primary outcome measures are collected during the first 21 days.</time_frame>
    <description>The duration of making measurements during the first cycle is 21 days. All data relating to the primary outcome measure is collected during this time.
There is an optional Extension Phase during which subjects can continue to receive additional 21-day cycles of amrubicin unless there is evidence of tumor progression or unacceptable toxicity. The duration of measurements depends on how long the subject continues on treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the safety and tolerability of 40 mg/m2 amrubicin given as 5 minute IV infusions for 3 consecutive days; information will be collected by adverse event monitoring and laboratory safety tests.</measure>
    <time_frame>Cycle 1: all primary outcome measures are collected during the first 21 days.</time_frame>
    <description>The duration of making measurements during the first cycle is 21 days. All data relating to the primary outcome measure is collected during this time.
There is an optional Extension Phase during which subjects can continue to receive additional 21-day cycles of amrubicin unless there is evidence of tumor progression or unacceptable toxicity. The duration of measurements depends on how long the subject continues on treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Explore the relationship between pharmacokinetics and QTc interval change. Information will be obtained by further analysis of the datasets obtained from the primary outcome measures</measure>
    <time_frame>Cycle 1: all primary outcome measures are collected during the first 21 days.</time_frame>
    <description>The duration of making measurements during the first cycle is 21 days. All data relating to the primary outcome measure is collected during this time.
There is an optional Extension Phase during which subjects can continue to receive additional 21-day cycles of amrubicin unless there is evidence of tumor progression or unacceptable toxicity. The duration of measurements depends on how long the subject continues on treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Amrubicin 40mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 &amp; 3 of a 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amrubicin</intervention_name>
    <description>40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)</description>
    <arm_group_label>Amrubicin 40mg/m^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting all of the following criteria will be considered for enrollment into
             the study:

               1. Males or females, aged 18-65 years;

               2. Histological or cytological diagnosis of solid malignancy for which no acceptable
                  standard therapy exists or for which approved standard therapy has failed;

               3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

               4. Life expectancy greater than 3 months;

               5. Nonsmoker or not smoked or used tobacco products for at least 3 months before the
                  screening visit and agree to abstain from smoking/using tobacco products
                  throughout the formal study and until the End of Study visit;

               6. Capable of giving informed consent, has signed the informed consent form, and is
                  willing to comply with scheduled visits, dose administration, and other study
                  procedures;

               7. Women of childbearing potential may participate, providing they have a negative
                  serum pregnancy test (β-HCG) at screening, and a negative urine pregnancy test
                  prior to dosing on Day 1 of each cycle;

               8. Males and females of childbearing potential must agree to the use of at least 2
                  effective contraceptive methods until at least 28 days following the last dose of
                  study drug;

               9. Serum potassium, magnesium and corrected calcium that is within institutional
                  normal range at screening;

              10. Adequate organ function including the following:

                    -  Adequate bone marrow reserve: absolute neutrophil count (segmented and
                       bands) (ANC) ≥1.5 x 109/L, platelet count ≥100 x 109/L, and hemoglobin ≥90
                       g/L,

                    -  Hepatic: bilirubin ≤1.5 x the upper limit of normal (ULN), ALT and AST ≤2.0
                       x ULN,

                    -  Renal: serum creatinine ≤1.5 x ULN or calculated creatinine clearance &gt;80
                       mL/min.

        Exclusion Criteria:

          -  Patients meeting any of the following criteria will be excluded from the study:

               1. Hypersensitivity to amrubicin or related compounds;

               2. Radiotherapy with curative intent to a primary disease complex ≤ 28 days before
                  first dose; cranial radiotherapy ≤ 21 days before first dose; radiotherapy to all
                  other areas ≤ 7 days before first dose of amrubicin;

               3. History or presence of clinically significant abnormal 12-lead ECG or triplicate
                  ECGs with a mean QT interval corrected for heart rate (HR) using Fridericia's
                  method (QTcF) of &gt;450 msec (males) or &gt;470 msec (females), a PR interval &gt;240
                  msec or a QRS interval &gt;110 msec (within 3 months of screening visit);

               4. Left ventricular ejection fraction (LVEF) &lt;50%;

               5. Recent history (within 3 months of screening visit) of pericarditis and
                  pericardial effusion;

               6. History within 6 months of the screening visit of one of the following:

                    -  cardiac disease including congenital long-QT syndrome,

                    -  angina, congestive heart failure,

                    -  myocardial ischemia or infarction,

                    -  myocarditis, chest pain or dyspnea on exertion of cardiac origin,,

                    -  idiopathic or hypertrophic cardiomyopathy,

                    -  sarcoidosis,

                    -  syncope,

                    -  epilepsy,

                    -  or other clinically significant cardiac disease;

               7. Family history of long QT syndrome;

               8. Use of implantable pacemaker or implantable cardioverter defibrillator;

               9. Clinically significant bradycardia (&lt;50 beats per minute);

              10. Systolic blood pressure &gt;150 mmHg or diastolic blood pressure &gt;100 mmHg;

              11. Previous treatment with an investigational agent or any anticancer therapy within
                  4 weeks prior to the 'off-drug' visit;

              12. Previous treatment with anticancer therapy and has not fully recovered (Common
                  Terminology Criteria Adverse Event [CTCAE] Grade 1, except alopecia) from the
                  toxic effects of that treatment;

              13. Treatment with any medication known to produce QT prolongation enzyme-inducing
                  anticonvulsants, non-prescription medications including topical medications, all
                  vitamins, minerals, herbs or dietary supplements/remedies (e.g., Saint John's
                  Wort or Milk Thistle) for at least 7 days before the start of the off-drug visit;

              14. Previous treatment with any anthracycline;

              15. Any condition that would put the patient at undue risk or discomfort as a result
                  of adherence to study procedures;

              16. Women who are pregnant or nursing;

              17. Uncontrolled intercurrent illness such as myelosuppression, renal impairment,
                  hepatic impairment, infection and uncontrolled diabetes;

              18. Symptomatic central nervous system metastases. Patients with asymptomatic brain
                  metastases are allowed. The patient must be stable for ≥ 2 weeks after
                  radiotherapy, if the patient is on corticosteroids, the dose of corticosteroids
                  must have been stable for ≥ 2 weeks prior to the first dose of study treatment,
                  or be in the process of being tapered;

              19. Suspected, diffuse idiopathic interstitial lung disease or pulmonary fibrosis not
                  related to prior treatment;

              20. History of seropositive HIV or patients who are receiving immunosuppressive or
                  myelosuppressive medications that would, in the opinion of the investigator,
                  increase the risk of serious neutropenic complications;

              21. Positive urine drug screen for undeclared concomitant medications and/or illegal
                  drug use at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Renschler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Pavilion</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center at San Antonio- Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunstman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amrubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

